Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Acetyltryptophan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | ACE | P12821 | 3/20 | 0.57 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetyltryptophan SCHEMBL11481713 | 0.97 | TACR1 (0.64) | TACR1ALOX15POLBGAAKMT2A | |
| Acetyltryptophan SCHEMBL26911615 | 0.97 | TACR1 (0.64) | TACR1ALOX15POLBGAAKMT2A | |
| Acetyltryptophan SCHEMBL181483 | 0.97 | TACR1 (0.64) | TACR1ALOX15POLBGAAKMT2A | |
| Acetyltryptophan SCHEMBL181484 | 0.97 | TACR1 (0.64) | TACR1ALOX15POLBGAAKMT2A | |
| Acetyltryptophan SCHEMBL11472608 | 0.97 | TACR1 (0.64) | TACR1ALOX15POLBGAAKMT2A | |
| Acetyltryptophan SCHEMBL1205188 | 0.97 | TACR1 (0.64) | TACR1ALOX15POLBGAAKMT2A | |
| Acetyltryptophan SCHEMBL11471932 | 0.97 | TACR1 (0.64) | TACR1ALOX15POLBGAAKMT2A | |
| Acetyltryptophan SCHEMBL11472611 | 0.97 | TACR1 (0.64) | TACR1ALOX15POLBGAAKMT2A | |
| Acetyltryptophan SCHEMBL20422818 | 0.89 | KMT2A (0.68) | TACR1ALOX15POLBGAAKMT2A | |
| SCHEMBL13176572 | 0.88 | TACR1 (0.67) | TACR1ALOX15POLBKMT2AACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1669065-B1 | DRUG CONTAINING (2R)-2-PROPYLOCTANOIC ACID AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2012-07-18 | — | — | EP | disclosed |
| US-8053599-B2 | Drug containing (2R)-2-propyloctanoic acid as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-11-08 | — | — | US | disclosed |
| US-20070105956-A1 | Drug containing (2r)-2-propyloctanoic acid as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070066686-A1 | Infusion preparation containing (2r)-2-propyloctanoic acid as at the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-22 | — | — | US | disclosed |
| EP-1669065-A1 | DRUG CONTAINING (2R)-2-PROPYLOCTANOIC ACID AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-14 | — | — | EP | disclosed |
| EP-1669066-A1 | INFUSION PREPARATION CONTAINING (2R)-2-PROPYLOCTANOIC ACID AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105956-A1 | Drug containing (2r)-2-propyloctanoic acid as the active ingredient | PSEN2, PRNP, GRIK5 | TACR1 2156/4885ALOX15 74/4885POLB 3594/4885 |
| US-20070066686-A1 | Infusion preparation containing (2r)-2-propyloctanoic acid as at the active ingredient | PARK7, IDE, ATP6V1B2 | TACR1 1284/4885ALOX15 19/4885POLB 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.